Sanofi-Aventis Receives Positive Final NICE Guidance On Multaq

U.K. spending watchdog recommends Multaq for atrial fibrillation and biologic therapies for rheumatoid arthritis and psoriatic arthritis, but rejects imatinib for adjuvant therapy of gastrointestinal stromal tumors.